ST. LOUIS -- GenoMed, Inc. a Next Generation DM(TM) (Disease Management) company that uses its expertise in genomics to improve clinical outcomes, announced today that it will offer its patent-pending broad spectrum viral antidote to the nation during this coming flu season this fall and winter.
Because of difficulties that a major pharmaceutical company has experienced at a British factory, nearly half of the flu vaccine doses destined for the United States will not be delivered in time for this year's flu season. U.S. health authorities have already begun planning how to ration existing flu vaccine doses.
GenoMed has applied for patent protection on the use of a class of blood pressure medications in viral diseases, such as the flu. This is a totally novel approach. There is no shortage of these medications worldwide.
The Company has had 100 percent success in treating a small number of normal, immunocompetent patients suffering from West Nile virus encephalitis during the past two summers, including the elderly. GenoMed's first case series of eight patients was published in July, 2004 in Current Topics in Medicinal Chemistry, a peer-reviewed medical journal.
Both the White House Office of Science Technology & Policy and the Department of Homeland Security have expressed interest in GenoMed's potential broad-spectrum viral antidote. GenoMed will be meeting during October with the National Institute of Allergy and Infectious Diseases (NIAID) to discuss further testing of its approach against viral diseases, including influenza.
Source: GenoMed, Inc.
